Zydus receives USFDA's nod for Carbidopa Tablets

10 May 2018 Evaluate

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Carbidopa Tablets, 25 mg. It is used with a combination levodopa/carbidopa product to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). It will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has more than 190 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies

Zydus Lifesciences Share Price

1089.85 -7.30 (-0.67%)
13-Jun-2024 10:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1502.00
Dr. Reddys Lab 6060.90
Cipla 1536.55
Zydus Lifesciences 1089.85
Lupin 1613.15
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.